Jiahui Health and Gleneagles Hong Kong Hospital Partner for Integrated Healthcare Services
China-based Jiahui Health has entered into a strategic partnership with Gleneagles Hong Kong Hospital to...
Saints Sages Surgical Secures Series B Funding to Advance Energy-Based Devices
Shanghai-based Saints Sages Surgical Co., Ltd, a leading developer of high-value minimally invasive surgical products,...
Hainan Huluwa Pharmaceutical Gets NMPA Approval for Generic Briviact Clinical Study
China-based Hainan Huluwa Pharmaceutical Group Co., Ltd (SHA: 605199) has announced that it has received...
CSPC Pharmaceutical Group Partners with Insilico and XtalPi for AI-Driven Drug R&D
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced strategic partnership agreements with Insilico Medicine...
Luye Pharma Group Submits Market Approval Filing for Lurbinectedin in Metastatic SCLC in Macau
China-based Luye Pharma Group (HKG: 2186) has announced that a market approval filing has been...
magAssist Receives FDA Breakthrough Device Designation for NyokAssist VAD
magAssist, a firm based in Suzhou, China, has announced that it has received breakthrough device...
Auzone Biological Technology Gets FDA Approval for Edaravone Oral Preparations in ALS
Suzhou Auzone Biological Technology Co., Ltd. has received approval from the US Food and Drug...
RemeGen Ltd Reports 20.56% YOY Revenue Growth in H1 2023 Financial Results
China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has released its financial report for the first...
Gilead’s Magrolimab Phase III Trial for AML Faces Partial Hold by FDA
Gilead (NASDAQ: GILD) has announced that the US Food and Drug Administration (FDA) has imposed...
Ascentage Pharma’s 2023 Interim Report: 49% YOY Revenue Growth and Market Expansion
China-based Ascentage Pharma (HKG: 6855) has released its 2023 interim financial report, revealing a 49%...
Pfizer’s RSV Vaccine Abrysvo Receives FDA Authorization for Maternal Immunization
The US Food and Drug Administration (FDA) has authorized the use of Pfizer’s (NYSE: PFE)...
J&J’s Teclistamab Granted Priority Review in China for Relapsed Multiple Myeloma
The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson’s (J&J, NYSE:...
Ascletis Pharma Inc. Reports 21.7% Revenue Increase in H1 2023, Led by Ritonavir Sales
China-based Ascletis Pharma Inc., (HKG: 1672) has revealed revenues of RMB 46.51 million (USD 6.38...
New Horizon Health Ltd Reports 264.6% YOY Revenue Increase and First Recurring Profits
China-based New Horizon Health Ltd (HKG: 6606), a leading cancer diagnostics developer, has released its...
Amgen’s Lumakras Faces Full Registration Review by FDA for KRAS-Mutated NSCLC
The US Food and Drug Administration (FDA) is scheduled to review an application submitted by...
AstraZeneca’s Forxiga Demonstrates Clinical Benefits in Heart Failure and COPD Patients
UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced evidence that its SGLT2 inhibitor, Forxiga...
NHSA Releases Preliminary Review Results for National Reimbursement Drug List Adjustments
The National Healthcare Security Administration (NHSA) has released a notification disclosing the drugs that have...
Novartis Sets Tentative Date for Sandoz Spin-Off, Targets October 4
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced October 4 of this year as the...
Jiangsu Hengrui Pharmaceuticals Reports 9.19% YOY Revenue Growth in H1 2023 Financial Report
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has released its financial report for the first...
AstraZeneca’s Forxiga Gains New Indication Approval in China for Chronic Heart Failure
UK-based pharmaceutical major AstraZeneca plc (AZ, NASDAQ: AZN) has announced that China’s National Medical Products...